HER-2阳性乳腺癌抗HER-2药物治疗的心脏毒性研究进展

临床肿瘤学杂志

HER-2阳性乳腺癌抗HER-2药物治疗的心脏毒性研究进展

曾化桂综述，欧阳取长审校

410013 长沙湖南省肿瘤医院乳腺内科

收稿日期:2016-08-05 修回日期:2016-10-14 出版日期:2017-04-30 发布日期:2017-04-30
通讯作者: 欧阳取长

Progression of cardiotoxicity due to anti-HER-2 medication on patients with HER-2 positive breast cancer

ZENG Huagui，OUYANG Quchang

Department of Breast Internal Medicine，Hunan Cancer Hospital，Changsha 410013，China

Received:2016-08-05 Revised:2016-10-14 Online:2017-04-30 Published:2017-04-30
Contact: OUYANG Quchang

摘要/Abstract

摘要：

抗人表皮生长因子受体2（HER-2）治疗明显改善了HER-2阳性乳腺癌患者的预后，曲妥珠单抗、帕妥珠单抗、拉帕替尼、T-DM1这4种靶向药物是目前乳腺癌抗HER-2治疗的主要选择。心脏毒性一直是抗HER-2治疗的重要不良反应，甚至危及生命，其表现形式多样，但可进行防治。了解靶向药物心脏毒性的表现形式、发生概率及防治手段有助于抗HER-2治疗的顺利进行。

Abstract:

Anti-human epidermal growth factor receptor-2（HER-2）therapies improved the prognosis of patients with HER-2 positive breast cancer. Trastuzumab，pertuzuma，lapatinib and T-DM1 are the major choices for these patients at present. Cardiotoxicity is one of the side effects of anti-HER-2 drugs and it puts patients at a risky position，which contains various manifestations and can be prevented and cured. Having knowledge of its symptoms，probabilities as well as its preventions and treatment helps to the process of anti-HER-2 treatment.

曾化桂综述，欧阳取长审校. HER-2阳性乳腺癌抗HER-2药物治疗的心脏毒性研究进展[J]. 临床肿瘤学杂志, 2017, 22(4): 362-.

ZENG Huagui，OUYANG Quchang. Progression of cardiotoxicity due to anti-HER-2 medication on patients with HER-2 positive breast cancer[J]. Chinese Clinical Oncology, 2017, 22(4): 362-.

参考文献

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed